Patents by Inventor Gunnar J. Hanson

Gunnar J. Hanson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200377886
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 3, 2020
    Applicant: SAREPTA THERAPEUTICS, INC.
    Inventors: Marco A. PASSINI, Gunnar J. HANSON
  • Publication number: 20200362339
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Application
    Filed: September 25, 2018
    Publication date: November 19, 2020
    Inventors: Kyle A. Totaro, Mark D. Simon, Ming Zhou, Hong Zong, Gunnar J. Hanson, Bradley L. Pentelute
  • Publication number: 20200316210
    Abstract: Provided herein are oligonucleotides, cell penetrating peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.
    Type: Application
    Filed: October 17, 2018
    Publication date: October 8, 2020
    Inventors: Justin M. Wolfe, Colin M. Fadzen, Zi-Ning Choo, Rebecca L. Holden, Monica Yao, Gunnar J. Hanson, Bradley L. Pentelute
  • Patent number: 10765760
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: September 8, 2020
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Marco A. Passini, Frederick Joseph Schnell
  • Publication number: 20200277598
    Abstract: Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: October 4, 2019
    Publication date: September 3, 2020
    Inventor: Gunnar J. Hanson
  • Patent number: 10760078
    Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: September 1, 2020
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Gunnar J. Hanson, Alexander Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • Publication number: 20200254109
    Abstract: Provided herein are oligonucleotides, peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.
    Type: Application
    Filed: April 28, 2020
    Publication date: August 13, 2020
    Inventors: Gunnar J. Hanson, Ming Zhou
  • Publication number: 20200237922
    Abstract: Provided herein are oligonucleotides, bicyclic peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.
    Type: Application
    Filed: October 17, 2018
    Publication date: July 30, 2020
    Inventors: Justin M. Wolfe, Colin M. Fadzen, Rebecca L. Holden, Monica Yao, Gunnar J. Hanson, Bradley L. Pentelute
  • Patent number: 10675356
    Abstract: Provided herein are oligonucleotides, peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: June 9, 2020
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Gunnar J. Hanson, Ming Zhou
  • Publication number: 20200115709
    Abstract: Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: May 20, 2019
    Publication date: April 16, 2020
    Inventors: Gunnar J. Hanson, Dwight D. Weller, Bao Zhong Cai, Ming Zhou
  • Publication number: 20200078465
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 12, 2020
    Inventors: Marco A. PASSINI, Gunnar J. HANSON
  • Publication number: 20190365919
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 5, 2019
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Marco A. Passini, Frederick Joseph Schnell
  • Patent number: 10487326
    Abstract: Oligonucleotide analogs conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: November 26, 2019
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventor: Gunnar J. Hanson
  • Publication number: 20190264210
    Abstract: Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1.
    Type: Application
    Filed: October 18, 2018
    Publication date: August 29, 2019
    Inventors: Ryszard Kole, Gunnar J. Hanson
  • Publication number: 20190218551
    Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: December 19, 2018
    Publication date: July 18, 2019
    Inventors: Gunnar J. Hanson, Alexander Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • Patent number: 10344281
    Abstract: Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: July 9, 2019
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Gunnar J. Hanson, Dwight D. Weller, Bao Zhong Cai, Ming Zhou
  • Publication number: 20190100755
    Abstract: The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.
    Type: Application
    Filed: July 18, 2018
    Publication date: April 4, 2019
    Inventors: Peter Linsley, Brian James Leppert, Gunnar J. Hanson
  • Patent number: 10202602
    Abstract: Oligonucleotide analogs comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: February 12, 2019
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Gunnar J. Hanson, Alexander Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • Publication number: 20190030176
    Abstract: Provided herein are peptide-oligomer-conjugates. Also provided herein are methods of treating a central nervous system disorder, a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject peptide-oligomer-conjugates described herein.
    Type: Application
    Filed: December 14, 2016
    Publication date: January 31, 2019
    Inventors: Gunnar J. Hanson, Ming Zhou
  • Publication number: 20190015440
    Abstract: The present disclosure relates to modified antisense oligomers and related compositions and methods for increasing the expression of functional SMN protein and methods for treating spinal muscular atrophy and relates to inducing inclusion of exon 7 in SMN2 mRNA.
    Type: Application
    Filed: August 26, 2016
    Publication date: January 17, 2019
    Inventors: Marco A. Passini, Gunnar J. Hanson